Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 29 Oct 2026
Underserved or high-risk populations

CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States

CAR-T therapy recipients experienced longer delays before needing additional treatment, though only a small fraction of eligible patients currently access it.

This retrospective claims-based cohort study examined CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States. Only 20% of eligible patients were referred and 15% received CAR-T, while recipients had longer time to next treatment or death than nonrecipients.

What the study was

Study design
Retrospective claims-based cohort study
Population
US adults with relapsed or refractory large B-cell lymphoma after at least two prior treatment lines
Sample size
8,959 patients
Category
Public Health
Maturity
Validated
Journal
Blood advances

Why it surfaced

Retrospective claims-based cohort study; Only 20% of eligible patients were referred and 15% received CAR-T, while recipients had longer time to next treatment or death than nonrecipients. Score kept conservative because only the PubMed abstract and metadata were reviewed.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.